Quick Takeaways:
- Cronus Pharma has launched Florfinasone Otic, an FDA-approved fixed-combination treatment for otitis externa in dogs caused by susceptible Malassezia pachydermatis yeast and Staphylococcus pseudintermedius bacteria.
- The single-use formulation combines florfenicol (antibacterial), terbinafine (antifungal), and mometasone furoate (anti-inflammatory), providing three complementary activities in one treatment.
- Approved under ANADA #200-848, Florfinasone Otic is available in 1 mL single-use dropperettes through national and regional distributors. The tympanic membrane should be confirmed intact before use, and the product is not indicated for cats.
Why It Matters?
Cronus Pharma’s launch of Florfinasone Otic (florfenicol + terbinafine + mometasone) adds an FDA‑approved, single‑use, triple‑action topical for canine otitis externa to a growing companion‑animal ear‑infection market. The fixed‑dose combination simplifies empiric therapy for mixed yeast/bacterial cases and leverages convenient 1 mL dropperettes distributed nationally/regionally, positioning Florfinasone against other multi‑ingredient otics (e.g., Osurnia, Claro, Otiserene) in a segment where topical combination drugs are gaining share amid high otitis externa prevalence and rising pet‑care spend.
Source: Businesswire
